546112-35-0Relevant academic research and scientific papers
2-Methylquinoline promoted oxidative ring-opening of N-sulfonyl aziridines with DMSO: facile synthesis of α-amino aryl ketones
Zhang, Xianhui,Li, Shuai-Shuai,Wang, Liang,Xu, Lubin,Xiao, Jian,Liu, Zhen-Jiang
, p. 8073 - 8077 (2016)
2-Methylquinoline promoted room-temperature oxidative ring-opening of N-sulfonyl aziridines with DMSO has been developed, providing a mild and convenient method for the synthesis of a variety of different N-sulfonyl protected α-amino aryl ketones. The employment of 2-methylquinoline was crucial for the success of this mild transformation and good to excellent yields could be achieved.
M-STAGE KINESIN INHIBITOR
-
Page/Page column 81, (2010/11/08)
A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, -C(=W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents -C(=Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.
11-Beta HSD1 inhibitors
-
Page/Page column 26, (2008/06/13)
This invention relates to inhibiting 11-beta HSD1.
THIADIAZOLINE DERIVATIVE
-
Page 56, (2010/02/08)
(wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents -C(-W)R6 or the like; R3 represents a hydrogen atom, -C(=WA)R6A, or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
